Possible Influence of Loxoprofen in Lipopolysaccharide Induced Alterations in Brain Serotonin, Noradrenaline and Dopamine Levels in Chronic Mild Stress Treated Mice

Abstract

The objective of the present study was to evaluate the influence of Loxoprofen on serotonin, noradrenaline and dopamine levels in absence or presence of Lipopolysaccharide (LPS) after chronic mild stress treatment in mice brain. Background: It has been reported that there is an abnormal prostaglandin levels in depression. Several studies indicated that there has been an elevated level of prostaglandins in depression. It has been reported that Loxoprofen remarkably decrease the PGE2 level in regions of brain. Method: There was an estimation of serotonin, noradrenaline and dopamine levels in mice brain after 21 days of chronic mild stress schedule in which mice were subjected to treatment of Loxoprofen (16.8mg/kg, p.o.) or Venlafexine (4mg/kg, i.p.) with or without treatment of LPS (0.5mg/kg, i.p.) for last 14 days. Results: There was a significant decrease in brain serotonin, noradrenaline and dopamine levels in stressed mice as compared to normal mice. There was a significant decrease in brain serotonin, noradrenaline and dopamine levels in LPS treated stressed mice as compared to LPS treated normal mice. The treatment of Loxoprofen in LPS treated stressed mice showed a significant increase in brain serotonin and noradrenaline levels but not dopamine levels as compared to LPS treated stressed mice. The treatment of Venlafexine in LPS treated stressed mice showed a significant increase in all above mentioned three brain neurotransmitters levels as compared to LPS treated stressed mice.Conclusion: The results of the present study showed that Loxoprofen influence the LPS induced alterations in serotonin and noradrenaline levels in mice brain after 21 day exposure of chronic mild stress schedule. It can indicate the possible antidepressant-like effect of Loxoprofen in mice subjected to chronic mild stress schedule, having its possible implication in future treatment of depression.